Skip Navigation


European Heart Journal Advance Access originally published online on June 7, 2006
European Heart Journal 2006 27(13):1584-1591; doi:10.1093/eurheartj/ehl082
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
27/13/1584    most recent
ehl082v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Budeus, M.
Right arrow Articles by Perings, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Budeus, M.
Right arrow Articles by Perings, C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Amiodarone prophylaxis for atrial fibrillation of high-risk patients after coronary bypass grafting: a prospective, double-blinded, placebo-controlled, randomized study

Marco Budeus1,*, Marcus Hennersdorf3, Stefan Perings3, Shinga Röhlen3, Stefan Schnitzler3, Oliver Felix3, Klaus Reimert3, Peter Feindt4, Emmeran Gams4, Nils Lehmann2, Heinrich Wieneke1, Stefan Sack1, Raimund Erbel1 and Christian Perings5

1 Department of Cardiology, West-German Heart Centre, University of Duisburg-Essen Hufelandstr, 55 D-45122 Essen, Germany
2 Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Germany
3 Department of Cardiology, Pneumology and Angiology, Medical Clinic and Policlinic B, Heinrich-Heine-University, Duesseldorf, Germany
4 Department of Thorax- and Cardiovascular Surgery, Surgical Clinic and Policlinic B, Heinrich-Heine-University, Duesseldorf, Germany
5 Department of Cardiology and Angiology, University Hospital Herne, Ruhr-University Bochum, Herne, Germany

Received 30 December 2005; revised 12 April 2006; accepted 19 May 2006; online publish-ahead-of-print 7 June 2006.

* Corresponding author. Tel: +49 201 7234801; fax: +49 201 7235401.E-mail address: marco.budeus{at}medizin.uni-essen.de

Aims Atrial fibrillation (AF) occurs often in patients after coronary artery bypass grafting (CABG) and can result in increased morbidity and mortality. Previous studies using P-wave signal-averaged electrocardiogram (P-SAECG) have shown that patients with a longer filtered P-wave duration (FPD) have a high risk of AF after CABG. We have shown that patients with an FPD≥124 ms and a root-mean-square voltage of the last 20 ms of the P-wave 20≤3.7 µV have an increased risk of AF after surgery. Accordingly, the aim of this study was to investigate whether or not prophylactic peri-operative administration of amiodarone could reduce the incidence of AF in this high-risk group undergoing CABG identified by P-SAECG.

Methods and results In this prospective, double-blinded, placebo-controlled, randomized study, 110 patients received either amiodarone (n=55) or placebo (n=55). During CABG, two patients of both groups died. Amiodarone was given as 600 mg oral single dose one day before and from days 2 through 7 after surgery. In addition, amiodarone was also administered intravenously during surgery in a 300-mg bolus for 1 h and as a total maintenance dose of 20 mg/kg weight over 24 h on the first day following surgery. The primary endpoint was the occurrence of AF after CABG. The secondary endpoint was the hospitalization length of stay after CABG. The baseline characteristics were similar in both treatment groups. The incidence of post-operative AF was significantly higher in the placebo group compared with the amiodarone group (85 vs. 34% of patients, P<0.0001). The prophylactic therapy with amiodarone significantly reduced the intensive care (1.8±1.7 vs. 2.4±1.5 days, P=0.001) and hospitalization length of stay (11.3±3.4 vs. 13.0±4.3 days, P=0.03). In the amiodarone group, concentrations of amiodarone and desethylamiodarone differed significantly between patients with AF and sinus rhythm (amiodarone: 0.96±0.5 vs. 0.62±0.4 µg/mL, P=0.02; desethylamiodarone: 0.65±0.2 vs. 0.48±0.1 µg/mL, P=0.04).

Conclusion The incidence of post-operative AF among high-risk patients was significantly reduced by a prophylactic amiodarone treatment resulting in a shorter time of intensive care unit and hospital stay. Our data supports the prophylactic use of amiodarone in peri-operative period in patients at high risk for AF after CABG.

Key Words: P-wave signal averaged ECG • Atrial fibrillation • Coronary bypass grafting • Amiodarone


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
CirculationHome page
R. Cavolli, K. Kaya, A. Aslan, O. Emiroglu, S. Erturk, O. Korkmaz, M. Oguz, R. Tasoz, and U. Ozyurda
Does Sodium Nitroprusside Decrease the Incidence of Atrial Fibrillation After Myocardial Revascularization?: A Pilot Study
Circulation, July 29, 2008; 118(5): 476 - 481.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
L. R. Zebis, T. D. Christensen, I. S. Kristiansen, and V. E. Hjortdal
Amiodarone Cost Effectiveness in Preventing Atrial Fibrillation After Coronary Artery Bypass Graft Surgery
Ann. Thorac. Surg., January 1, 2008; 85(1): 28 - 32.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.